Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.

Escorcia FE, Houghton JL, Abdel-Atti D, Pereira PR, Cho A, Gutsche NT, Baidoo KE, Lewis JS.

Theranostics. 2020 Jan 1;10(1):151-165. doi: 10.7150/thno.37098. eCollection 2020.

2.

Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Milenic DE, Kim YS, Baidoo KE, Wong KJ, Barkley R, Delgado J, Brechbiel MW.

Cancer Biother Radiopharm. 2018 Jun;33(5):182-193. doi: 10.1089/cbr.2018.2434.

3.

Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW.

Dalton Trans. 2017 Oct 31;46(42):14591-14601. doi: 10.1039/c7dt01819c.

4.

Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.

Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW.

Transl Oncol. 2017 Aug;10(4):535-545. doi: 10.1016/j.tranon.2017.04.004. Epub 2017 May 31.

5.

Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.

PLoS One. 2016 Jul 28;11(7):e0159904. doi: 10.1371/journal.pone.0159904. eCollection 2016.

6.
7.

Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial.

Milenic DE, Baidoo KE, Brechbiel MW.

Pharmaceuticals (Basel). 2015 Jul 29;8(3):435-54. doi: 10.3390/ph8030435.

8.

Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.

Milenic DE, Molinolo AA, Solivella MS, Banaga E, Torgue J, Besnainou S, Brechbiel MW, Baidoo KE.

Pharmaceuticals (Basel). 2015 Jul 24;8(3):416-34. doi: 10.3390/ph8030416.

9.

Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent.

Kim YS, Zhou Y, Bryant H Jr, Milenic DE, Baidoo KE, Lewis BK, Frank JA, Brechbiel MW.

Bioorg Med Chem Lett. 2015;25(10):2056-9. doi: 10.1016/j.bmcl.2015.03.092. Epub 2015 Apr 4.

10.

Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG.

J Nucl Med. 2015 Apr;56(4):628-34. doi: 10.2967/jnumed.114.149062. Epub 2015 Feb 26.

11.

Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.

Milenic DE, Baidoo KE, Kim YS, Brechbiel MW.

MAbs. 2015;7(1):255-64. doi: 10.4161/19420862.2014.985160. Erratum in: MAbs. 2016;8(1):196.

12.

Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.

PLoS One. 2014 Sep 30;9(9):e108511. doi: 10.1371/journal.pone.0108511. eCollection 2014.

13.

In vitro and in vivo analysis of indocyanine green-labeled panitumumab for optical imaging-a cautionary tale.

Zhou Y, Kim YS, Milenic DE, Baidoo KE, Brechbiel MW.

Bioconjug Chem. 2014 Oct 15;25(10):1801-10. doi: 10.1021/bc500312w. Epub 2014 Oct 3.

14.

Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.

Yong KJ, Milenic DE, Baidoo KE, Kim YS, Brechbiel MW.

Cancer Med. 2013 Oct;2(5):646-53. doi: 10.1002/cam4.132. Epub 2013 Sep 19.

15.

Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.

Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW.

Cancer Biother Radiopharm. 2013 Jul-Aug;28(6):441-9. doi: 10.1089/cbr.2012.1423. Epub 2013 Jun 11.

16.

Methodology for labeling proteins and peptides with lead-212 (212Pb).

Baidoo KE, Milenic DE, Brechbiel MW.

Nucl Med Biol. 2013 Jul;40(5):592-9. doi: 10.1016/j.nucmedbio.2013.01.010. Epub 2013 Apr 17.

17.

Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.

Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong HS.

Nucl Med Biol. 2013 Jul;40(5):600-5. doi: 10.1016/j.nucmedbio.2013.01.012. Epub 2013 Mar 27.

18.

Molecular pathways: targeted α-particle radiation therapy.

Baidoo KE, Yong K, Brechbiel MW.

Clin Cancer Res. 2013 Feb 1;19(3):530-7. doi: 10.1158/1078-0432.CCR-12-0298. Epub 2012 Dec 10. Review.

19.

Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1119-26. doi: 10.1016/j.ijrobp.2012.09.015. Epub 2012 Nov 29.

20.

(111)In- and (203)Pb-Labeled Cyclic RGD Peptide Conjugate as an α(v)β(3) Integrin-Binding Radiotracer.

Nwe K, Kim YS, Milenic DE, Baidoo KE, Brechbiel MW.

J Labelled Comp Radiopharm. 2012 Sep 1;55(11):423-426. Epub 2012 Sep 5.

Supplemental Content

Loading ...
Support Center